Learning Objective:

1. Determine when to consider monitoring, directed therapy, systemic therapy, clinical trials or off-label use of kinase inhibitors.
2. Discuss the current literature on dedifferentiation therapy.

Faculty/Presenter:

Bryan Haugen, MD, Presenter, has no relevant financial relationships to disclose.

Faculty member does not plan on discussing unlabeled/investigational uses of a commercial product.